A
ARBUTUS BIOPHARMA CORP
NASDAQ: ABUS (Arbutus Biopharma Corporation)
Last update: 9 hours ago3.23
-0.28 (-7.98%)
| Previous Close | 3.51 |
| Open | 3.41 |
| Volume | 1,499,099 |
| Avg. Volume (3M) | 928,462 |
| Market Cap | 618,480,384 |
| Price / Sales | 97.15 |
| Price / Book | 6.35 |
| 52 Weeks Range | |
| Earnings Date | 30 Apr 2025 - 5 May 2025 |
| Operating Margin (TTM) | -995.43% |
| Diluted EPS (TTM) | -0.380 |
| Quarterly Revenue Growth (YOY) | -26.60% |
| Total Debt/Equity (MRQ) | 6.28% |
| Current Ratio (MRQ) | 8.15 |
| Operating Cash Flow (TTM) | -64.85 M |
| Levered Free Cash Flow (TTM) | -41.56 M |
| Return on Assets (TTM) | -33.36% |
| Return on Equity (TTM) | -68.76% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Arbutus Biopharma Corporation | Mixed | Bullish |
AIStockmoo Score
2.4
| Analyst Consensus | 2.5 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | 4.0 |
| Average | 2.38 |
|
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 22.03% |
| % Held by Institutions | 54.77% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Blackbarn Capital Partners Lp | 31 Dec 2024 | 2,341,871 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 5.00 (Chardan Capital, 54.80%) | Buy |
| 5.00 (HC Wainwright & Co., 54.80%) | Buy | |
| Median | 5.00 (54.80%) | |
| Average | 5.00 (54.80%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 3.36 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Chardan Capital | 28 Mar 2025 | 5.00 (54.80%) | Buy | 3.50 |
| HC Wainwright & Co. | 21 Jan 2025 | 5.00 (54.80%) | Buy | 3.21 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 27 Mar 2025 | Announcement | Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update |
| 03 Mar 2025 | Announcement | Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna |
| 13 Jan 2025 | Announcement | Arbutus Provides 2025 Corporate and Financial Update |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |